Welcome to the UPF Digital Repository

Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Show simple item record

dc.contributor.author Garrido, P.
dc.contributor.author Conde, Esther
dc.contributor.author De Castro, Javier
dc.contributor.author Gómez-Román, J. J.
dc.contributor.author Felip, Enriqueta
dc.contributor.author Pijuan Andujar, Lara
dc.contributor.author Isla, Dolores
dc.contributor.author Sanz, J.
dc.contributor.author Paz-Ares, L.
dc.contributor.author López-Ríos, F.
dc.date.accessioned 2020-05-08T07:34:49Z
dc.date.issued 2020
dc.identifier.citation Garrido P, Conde E, de Castro J, Gómez-Román JJ, Felip E, Pijuan L, et al. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2020 Jul;22(7):989-1003. DOI: 10.1007/s12094-019-02218-4
dc.identifier.issn 1699-048X
dc.identifier.uri http://hdl.handle.net/10230/44463
dc.description.abstract In 2011 the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) started a joint project to establish guidelines on biomarker testing in patients with advanced non-small-cell lung cancer (NSCLC) based on current evidence. As this field is constantly evolving, these guidelines have been updated, previously in 2012 and 2015 and now in 2019. Current evidence suggests that the mandatory tests to conduct in all patients with advanced NSCLC are for EGFR and BRAF mutations, ALK and ROS1 rearrangements and PD-L1 expression. The growing need to study other emerging biomarkers has promoted the routine use of massive sequencing (next-generation sequencing, NGS). The coordination of every professional involved and the prioritisation of the most suitable tests and technologies for each case remains a challenge.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Springer
dc.relation.ispartof Clinical and Translational Oncology. 2020 Jul;22(7):989-1003.
dc.rights © Springer The final publication is available at Springer via http://dx.doi.org/10.1007/s12094-019-02218-4
dc.title Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1007/s12094-019-02218-4
dc.subject.keyword ALK
dc.subject.keyword BRAF
dc.subject.keyword Biomarkers
dc.subject.keyword EGFR
dc.subject.keyword Non-small-cell lung cancer
dc.subject.keyword PD-L1
dc.subject.keyword ROS1
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/acceptedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking